# Edie Weller

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/edie-weller/

## Facts

| Field | Value |
| --- | --- |
| Citations | 16,553 |
| Field | Multiple Myeloma Research and Treatments |
| h-index | 60 |
| i10-index | 116 |
| Last Known Institution | Boston Children's Hospital |
| OpenAlex ID | https://openalex.org/A5000527476 |
| Works | 231 |

## Researcher papers

- [Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma](https://scholariq.org/papers/rituximab-chop-versus-chop-alone-or-with-maintenance-rituximab-in-older-patients/)
- [Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma](https://scholariq.org/papers/lenalidomide-bortezomib-and-dexamethasone-with-transplantation-for-myeloma/)
- [Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma](https://scholariq.org/papers/lenalidomide-bortezomib-and-dexamethasone-combination-therapy-in-patients-with/)
- [Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma](https://scholariq.org/papers/immunomodulatory-drug-cc-5013-overcomes-drug-resistance-and-is-well-tolerated-in/)
- [BM mesenchymal stromal cell–derived exosomes facilitate multiple myeloma progression](https://scholariq.org/papers/bm-mesenchymal-stromal-cell-derived-exosomes-facilitate-multiple-myeloma/)
- [A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma](https://scholariq.org/papers/a-randomized-phase-2-study-of-lenalidomide-therapy-for-patients-with-relapsed-or/)
- [Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma](https://scholariq.org/papers/triplet-therapy-transplantation-and-maintenance-until-progression-in-myeloma/)
- [Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu](https://scholariq.org/papers/anti-cs1-humanized-monoclonal-antibody-huluc63-inhibits-myeloma-cell-adhesion/)
- [Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial](https://scholariq.org/papers/disabling-immune-tolerance-by-programmed-death-1-blockade-with-pidilizumab-after/)
- [Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors](https://scholariq.org/papers/second-malignancy-after-hodgkin-disease-treated-with-radiation-therapy-with-or/)
- [Effectiveness of Maternal Vaccination with mRNA COVID-19 Vaccine During Pregnancy Against COVID-19–Associated Hospitalization in Infants Aged <6 Months — 17 States, July 2021–January 2022](https://scholariq.org/papers/effectiveness-of-maternal-vaccination-with-mrna-covid-19-vaccine-during/)
- [Defining disrupted nighttime sleep and assessing its diagnostic utility for pediatric narcolepsy type 1](https://scholariq.org/papers/defining-disrupted-nighttime-sleep-and-assessing-its-diagnostic-utility-for/)

## Researcher topics

- [Multiple Myeloma Research and Treatments](https://scholariq.org/topics/multiple-myeloma-research-and-treatments/)
- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)
- [Chronic Lymphocytic Leukemia Research](https://scholariq.org/topics/chronic-lymphocytic-leukemia-research/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Chronic Myeloid Leukemia Treatments](https://scholariq.org/topics/chronic-myeloid-leukemia-treatments/)

## Researcher university

- [Boston Children's Hospital](https://scholariq.org/institutions/boston-children-s-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.